Skip to main content

Table 3 Logistic regression results with prescriptions of anti-asthma medication as outcome

From: A longitudinal study of cannabis use increasing the use of asthma medication in young Norwegian adults

  Reference (OR = 1) Unadjusted Model 1 Model 2
OR 95% CI p OR 95% CI p OR 95% CI p
Female gender Male 1.79 1.22–2.41 < 0.001 2.00 1.45–2.75 < 0.001 2.15 1.51–3.05 < 0.001
Age Continuous 0.98 0.91–1.05 0.551 0.98 0.91–1.05 0.547 0.96 0.89–1.05 0.370
Education Continuous 0.98 0.92–1.05 0.615     0.97 0.90–1.05 0.442
Body mass index Continuous 1.01 0.98–1.05 0.423     1.04 1.00–1.08 0.050
Asthma at T1 No asthma 2.60 1.67–4.05 < 0.001 2.48 1.52–4.03 < 0.001 2.49 1.50–4.13 < 0.001
Allergies at T1 No allergies 1.58 1.15–2.17 0.005 1.38 0.98–1.95 0.067 1.51 1.05–2.17 0.025
Smoking at T4 Never smoked          
 Smoked daily before, but not now   1.47 0.99–2.18 0.054     1.15 0.73–1.83 0.540
 Smokes sometimes, but not daily   1.01 0.61–1.66 0.976     0.88 0.51–1.56 0.678
 Smokes daily   1.73 1.23–2.42 0.002     1.20 0.78–1.85 0.414
Cannabis use at T4 Never used cannabis          
 Used cannabis before, but not last year   0.83 0.57–1.22 0.342 0.85 0.57–1.27 0.423 0.82 0.53–1.28 0.378
 Used cannabis last year   1.65 1.14–2.41 0.009 2.05 1.38–3.05 < 0.001 1.71 1.06–2.77 0.028
  1. Note: OR = odds ratio; 95% CI = 95% confidence interval of OR
  2. Data on prescriptions are taken from the Norwegian Prescription Database and and explanatory variables are taken from the longitudinal Young in Norway Study. Model 1 includes adjustment for gender, age, self-reported asthma or allergies in addition to cannabis smoking. Model 2 includes additional adjustment for education, BMI and smoking